Literature DB >> 12607729

Casein is an essential cofactor in autoantibody reactivity directed against the C-terminal SmD1 peptide AA 83-119 in systemic lupus erythematosus.

Gabriela Riemekasten1, Jeannette Marell, Christian Hentschel, Rolf Klein, Gerd-R Burmester, Werner Schoessler, Falk Hiepe.   

Abstract

The C-terminal peptide SmD1(83-119) has been identified as an important autoantigen in systemic lupus erythematosus (SLE). ELISA studies have shown that roughly 70% of all sera from patients with SLE react with this peptide. Previous findings revealed that the addition of blocking agents and sample dilution buffers influences the discrimination between positive and negative anti-SmD1(83-119) sera in SLE. The aim of the present study was to identify possible cofactors in the anti-SmD1(83-119) reactivity. We therefore tested SLE sera (n=6) for anti-SmD1(83-119) reactivity by ELISA and analysed the effects of different blocking agents (1% skim milk, 1% gelatin, and 1% BSA). In our investigation, lipids were extracted from skim milk using dichlomethane, and the putative fraction was tested to assess the assay's ability to discriminate between positive and negative sera. The effects of enzymatic digestion by casein were analyzed, and different concentrations of casein were used to determine the role of this protein in the detection of anti-SmD1(83-119) antibodies by ELISA. Furthermore, rabbits were immunized with SmD1(83-119) adsorbed to casein and control proteins. One percent skim milk was the most effective blocking agent and sample dilution buffer for the discrimination between positive and negative sera. As demonstrated by SDS electrophoresis, the discriminative capacity was influenced by enzymatic digestion of skim milk proteins, but not by lipid extraction. Differences in anti-SmD1(83-119) reactivity upon variation of the casein concentration suggest that the protein plays a significant role in the detection of anti-SmD1(83-119) antibodies. However, our immunisation studies did not show any effect of casein on anti-SmD1(83-119) reactivity, suggesting that it has no immunogenic effect on the anti-SmD1(83-119) response. In conclusion, casein seems to be an important cofactor in autoantibody reactivity directed against the C-terminal SmD1(83-119) peptide and probably functions by changing the conformation of the peptide's critical epitope.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12607729     DOI: 10.1078/0171-2985-00202

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  6 in total

1.  The binding of lupus-derived autoantibodies to the C-terminal peptide (83-119) of the major SmD1 autoantigen can be mediated by double-stranded DNA and nucleosomes.

Authors:  J W Dieker; C C Van Bavel; G Riemekasten; J H Berden; J van der Vlag
Journal:  Ann Rheum Dis       Date:  2006-03-15       Impact factor: 19.103

2.  Mucosal reactivity to cow's milk protein in coeliac disease.

Authors:  G Kristjánsson; P Venge; R Hällgren
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

3.  Evaluating Anti-SmD1-amino-acid 83-119 Peptide Reactivity in Children with Systemic Lupus Erythematosus and Other Immunological Diseases.

Authors:  Hai-Ou Yang; Xiao-Qing Zhang; Qi-Hua Fu
Journal:  Chin Med J (Engl)       Date:  2016-12-05       Impact factor: 2.628

Review 4.  The Role of Exposomes in the Pathophysiology of Autoimmune Diseases I: Toxic Chemicals and Food.

Authors:  Aristo Vojdani; Elroy Vojdani
Journal:  Pathophysiology       Date:  2021-12-18

5.  Effect of dsDNA binding to SmD-derived peptides on clinical accuracy in the diagnosis of systemic lupus erythematosus.

Authors:  Michael Mahler; Aderajew Waka; F Hiepe; Marvin J Fritzler
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

Review 6.  Next-Generation Autoantibody Testing by Combination of Screening and Confirmation-the CytoBead® Technology.

Authors:  Mandy Sowa; Rico Hiemann; Peter Schierack; Dirk Reinhold; Karsten Conrad; Dirk Roggenbuck
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.